

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-12. (canceled)

13. (currently amended): A therapeutic or preventive method for cerebrovascular disorders comprising introducing a polynucleotide encoding a hepatocyte growth factor (HGF) gene and/or a polynucleotide encoding vascular endothelial growth factor (VEGF) gene in the form of hemagglutinating virus of Japan (HVJ)-liposomes by direct injection into the subarachnoid space in humans thereby treating or preventing said cerebrovascular disorders.

14. (currently amended): A therapeutic or preventive method for treating or preventing reduced blood flow comprising introducing a polynucleotide encoding a HGF gene and/or a polynucleotide encoding VEGF gene in the form of HVJ-liposomes by direct injection into the subarachnoid space in humans thereby treating or preventing said reduced blood flow.

15. (currently amended): A method of promoting cerebral angiogenesis comprising introducing a polynucleotide encoding a HGF gene and/or a polynucleotide encoding VEGF

gene in the form of HVJ-liposomes by direct injection into the subarachnoid space in humans thereby promoting said cerebral angiogenesis.

16. (currently amended): A method of suppressing neuronal death in the brain comprising introducing a polynucleotide encoding n-HGF gene in the form of HVJ-liposomes by direct injection into the subarachnoid space in humans thereby suppressing said neuronal death in the brain.

17. (currently amended): A method of suppressing apoptosis of nerve cells in the brain comprising introducing by direct injection a polynucleotide encoding n-HGF gene in the form of HVJ-liposomes into the subarachnoid space in humans thereby suppressing said apoptosis of nerve cells.

18.-25. (canceled).